A citation-based method for searching scientific literature

Rayna K Matsuno, Joseph P Costantino, Regina G Ziegler, Garnet L Anderson, Huilin Li, David Pee, Mitchell H Gail. J Natl Cancer Inst 2011
Times Cited: 97







List of co-cited articles
627 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
75

Projecting individualized absolute invasive breast cancer risk in African American women.
Mitchell H Gail, Joseph P Costantino, David Pee, Melissa Bondy, Lisa Newman, Mano Selvan, Garnet L Anderson, Kathleen E Malone, Polly A Marchbanks, Worta McCaskill-Stevens,[...]. J Natl Cancer Inst 2007
196
74

Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
506
49

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
693
43

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.
B Rockhill, D Spiegelman, C Byrne, D J Hunter, G A Colditz. J Natl Cancer Inst 2001
422
36

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
32

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.
Jeffrey A Tice, Steven R Cummings, Rebecca Smith-Bindman, Laura Ichikawa, William E Barlow, Karla Kerlikowske. Ann Intern Med 2008
349
30

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
21

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
394
20

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
574
20

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
846
19

Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.
Jinbo Chen, David Pee, Rajeev Ayyagari, Barry Graubard, Catherine Schairer, Celia Byrne, Jacques Benichou, Mitchell H Gail. J Natl Cancer Inst 2006
240
17

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
350
17

Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women.
Matthew P Banegas, Esther M John, Martha L Slattery, Scarlett Lin Gomez, Mandi Yu, Andrea Z LaCroix, David Pee, Rowan T Chlebowski, Lisa M Hines, Cynthia A Thompson,[...]. J Natl Cancer Inst 2016
26
65

Prospective breast cancer risk prediction model for women undergoing screening mammography.
William E Barlow, Emily White, Rachel Ballard-Barbash, Pamela M Vacek, Linda Titus-Ernstoff, Patricia A Carney, Jeffrey A Tice, Diana S M Buist, Berta M Geller, Robert Rosenberg,[...]. J Natl Cancer Inst 2006
286
16

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
M H Gail, J P Costantino, J Bryant, R Croyle, L Freedman, K Helzlsouer, V Vogel. J Natl Cancer Inst 1999
471
16

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
127
16

Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort.
Adam R Brentnall, Elaine F Harkness, Susan M Astley, Louise S Donnelly, Paula Stavrinos, Sarah Sampson, Lynne Fox, Jamie C Sergeant, Michelle N Harvie, Mary Wilson,[...]. Breast Cancer Res 2015
111
15

Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort.
Adriano Decarli, Stefano Calza, Giovanna Masala, Claudia Specchia, Domenico Palli, Mitchell H Gail. J Natl Cancer Inst 2006
72
19

Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.
E Amir, D G Evans, A Shenton, F Lalloo, A Moran, C Boggis, M Wilson, A Howell. J Med Genet 2003
186
14

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
207
14

Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.
Anne S Quante, Alice S Whittemore, Tom Shriver, Konstantin Strauch, Mary B Terry. Breast Cancer Res 2012
71
19

Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Rowan T Chlebowski, Garnet L Anderson, Dorothy S Lane, Aaron K Aragaki, Thomas Rohan, Shagufta Yasmeen, Gloria Sarto, Carol A Rosenberg, F Allan Hubbell. J Natl Cancer Inst 2007
94
13

Risk prediction models of breast cancer: a systematic review of model performances.
Thunyarat Anothaisintawee, Yot Teerawattananon, Chollathip Wiratkapun, Vijj Kasamesup, Ammarin Thakkinstian. Breast Cancer Res Treat 2012
72
18

The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
A C Antoniou, P P D Pharoah, P Smith, D F Easton. Br J Cancer 2004
296
13

Validation of the Gail et al. model for predicting individual breast cancer risk.
D Spiegelman, G A Colditz, D Hunter, E Hertzmark. J Natl Cancer Inst 1994
173
13

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
241
13

Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population.
Jeffrey A Tice, Steven R Cummings, Elad Ziv, Karla Kerlikowske. Breast Cancer Res Treat 2005
165
12


Mammographic density and the risk and detection of breast cancer.
Norman F Boyd, Helen Guo, Lisa J Martin, Limei Sun, Jennifer Stone, Eve Fishell, Roberta A Jong, Greg Hislop, Anna Chiarelli, Salomon Minkin,[...]. N Engl J Med 2007
12

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Andrew N Freedman, Barry I Graubard, Sowmya R Rao, Worta McCaskill-Stevens, Rachel Ballard-Barbash, Mitchell H Gail. J Natl Cancer Inst 2003
178
12



Contribution of three components to individual cancer risk predicting breast cancer risk in Italy.
P Boyle, M Mezzetti, C La Vecchia, S Franceschi, A Decarli, C Robertson. Eur J Cancer Prev 2004
31
35

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
11


Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
150
11

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
11


Breast cancer risk prediction using a clinical risk model and polygenic risk score.
Yiwey Shieh, Donglei Hu, Lin Ma, Scott Huntsman, Charlotte C Gard, Jessica W T Leung, Jeffrey A Tice, Celine M Vachon, Steven R Cummings, Karla Kerlikowske,[...]. Breast Cancer Res Treat 2016
75
14

Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
Jessica A Cintolo-Gonzalez, Danielle Braun, Amanda L Blackford, Emanuele Mazzola, Ahmet Acar, Jennifer K Plichta, Molly Griffin, Kevin S Hughes. Breast Cancer Res Treat 2017
80
13

Assessing women at high risk of breast cancer: a review of risk assessment models.
Eitan Amir, Orit C Freedman, Bostjan Seruga, D Gareth Evans. J Natl Cancer Inst 2010
269
10

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Elizabeth Barrett-Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle A McNabb, Nanette K Wenger. N Engl J Med 2006
679
10

Factors affecting breast cancer risk reduction practices among California physicians.
Celia Patricia Kaplan, Jennifer S Haas, Eliseo J Pérez-Stable, Genevieve Des Jarlais, Steven E Gregorich. Prev Med 2005
71
14

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
439
10

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
268
10

Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis.
Valerie A McCormack, Isabel dos Santos Silva. Cancer Epidemiol Biomarkers Prev 2006
10

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
Erika A Waters, Kathleen A Cronin, Barry I Graubard, Paul K Han, Andrew N Freedman. Cancer Epidemiol Biomarkers Prev 2010
109
9

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Jack Cuzick, John F Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell. J Natl Cancer Inst 2007
363
9

Performance of common genetic variants in breast-cancer risk models.
Sholom Wacholder, Patricia Hartge, Ross Prentice, Montserrat Garcia-Closas, Heather Spencer Feigelson, W Ryan Diver, Michael J Thun, David G Cox, Susan E Hankinson, Peter Kraft,[...]. N Engl J Med 2010
324
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.